Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dendreon and InterMune: Do They Mean Anything for the Regulatory Climate at FDA?

This article was originally published in RPM Report

Executive Summary

Provenge and pirfenidone were two of the most closely watched pending applications at FDA. The agency's decision on the two therapies may offer some insight into the current regulatory climate.

You may also be interested in...



Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade

Economists are fretting that the US may be heading into a “lost decade” of stagnation. Will those fears help Big Pharma investors finally end a lost decade of their own?

Pulmonary-Allergy Drugs: An Interview With FDA's Badrul Chowdhury

The Division of Pulmonary-Allergy Drugs has seen a number of high profile drugs come through its review group. The RPM Report sat down with Division Director Badrul Chowdhury to talk about his philosophy of drug review, the REMS, biosimilars, and the role of drug safety in making approval decisions.

Dendreon vs. CMS: "Full Coverage" or the CED Solution?

A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel